Agents inhibiting chronic rejection reactions after organ transplantation
AssigneeKissei Pharmaceutical Co., Ltd.
InventorsMitsuaki Isobe, Atsushi Izawa
Life of this patent
Estimating the term…
Abstract
The present invention relates to an agent for inhibiting diseases associated with chronic rejection after organ transplantation, such as transplanted heart-accelerated coronary arteriosclerosis, containing as an active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by formula: or a pharmaceutically acceptable salt thereof, which has an inhibitory effect on vascular thickening in transplanted hearts.
Claims3
A method for inhibiting chronic rejection after organ transplantation which comprises administering to a subject in need thereof a therapeutically effective amount of N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.